Education
About Us
Working with TipRanks
Follow Us
CAMP4 Therapeutics Corporation (CAMP)
NASDAQ:CAMP
CAMP Stock Chart & Stats
$3.39
-$0.13(-2.84%)
At close: 4:00 PM EST
$3.39
-$0.13(-2.84%)
Day’s Range― - ―
52-Week Range$1.31 - $10.80
Previous Close$4.45
Volume38.22K
Average Volume (3M)1.59M
Market Cap
$76.01M
Enterprise Value-$2.60M
Total Cash (Recent Filing)$39.05M
Total Debt (Recent Filing)$7.22M
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Mar 26, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding20,161,074
10 Day Avg. Volume141,089
30 Day Avg. Volume1,592,597
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)1.61
Price to Sales (P/S)156.16
P/FCF Ratio-2.21
Enterprise Value/Market Cap-0.03
Enterprise Value/Revenue-0.68
Enterprise Value/Gross Profit-0.68
Enterprise Value/Ebitda0.05
Forecast
1Y Price Target
$8.50Price Target Upside150.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe company has raised $50M in a private placement, providing a financial runway into 2027 and demonstrating investor confidence.
Research And DevelopmentCAMP4's focus on the CMP-002 program for SYNGAP1 mutation-related disorders indicates a strategic decision to enhance their core research areas.
Technology PlatformCAMP4's proprietary RNA-based technology platform shows strong potential to target a wide spectrum of haploinsufficient diseases.
Bears Say
Investment StrategyCAMP will not make any additional investment in the CMP-CPS-01 program and will explore partnership opportunities instead.
Market RatingThere is no price target on CAMP shares, and the lead program's early stage contributes to the Neutral rating.
Program DevelopmentThe lead program, CMP-SYNGAP-01 for SYNGAP-related disorders, is in a very early stage with a long time horizon to patient level value creation.
CAMP4 Therapeutics Corporation News
CAMP FAQ
What was CAMP4 Therapeutics Corporation’s price range in the past 12 months?
CAMP4 Therapeutics Corporation lowest stock price was $1.30 and its highest was $10.80 in the past 12 months.
What is CAMP4 Therapeutics Corporation’s market cap?
CAMP4 Therapeutics Corporation’s market cap is $76.01M.
When is CAMP4 Therapeutics Corporation’s upcoming earnings report date?
CAMP4 Therapeutics Corporation’s upcoming earnings report date is Mar 26, 2026 which is in 110 days.
How were CAMP4 Therapeutics Corporation’s earnings last quarter?
CAMP4 Therapeutics Corporation released its earnings results on Nov 20, 2025. The company reported -$0.55 earnings per share for the quarter, missing the consensus estimate of -$0.478 by -$0.072.
Is CAMP4 Therapeutics Corporation overvalued?
According to Wall Street analysts CAMP4 Therapeutics Corporation’s price is currently Undervalued.
Does CAMP4 Therapeutics Corporation pay dividends?
CAMP4 Therapeutics Corporation does not currently pay dividends.
What is CAMP4 Therapeutics Corporation’s EPS estimate?
CAMP4 Therapeutics Corporation’s EPS estimate is -0.34.
How many shares outstanding does CAMP4 Therapeutics Corporation have?
CAMP4 Therapeutics Corporation has 20,161,074 shares outstanding.
What happened to CAMP4 Therapeutics Corporation’s price movement after its last earnings report?
CAMP4 Therapeutics Corporation reported an EPS of -$0.55 in its last earnings report, missing expectations of -$0.478. Following the earnings report the stock price went down -17.379%.
Which hedge fund is a major shareholder of CAMP4 Therapeutics Corporation?
Currently, no hedge funds are holding shares in CAMP
CAMP4 Therapeutics Corporation Stock Smart Score
Company Description
CAMP4 Therapeutics Corporation
CAMP4 Therapeutics Corporation (CAMP) is a biotechnology company focused on harnessing the power of RNA biology to develop transformative therapies for patients with serious diseases. The company operates primarily in the biotechnology sector, with a strong emphasis on leveraging its proprietary CAMP4 platform, which utilizes advanced computational and experimental techniques to identify and develop novel therapeutic candidates. CAMP's core products and services include therapeutic programs targeting genetic disorders and other diseases, with a focus on RNA-targeted therapies that aim to modulate gene expression and restore normal cellular function.
CAMP Stock 12 Month Forecast
Average Price Target
$8.50
▲(150.74% Upside)
Technical Analysis
Relmada Therapeutics
―
Beyondspring
―
MiNK Therapeutics
―
Artiva Biotherapeutics, Inc.
―
OS Therapies Incorporated
―
Ownership Overview
31.11% Insiders
2.37% Mutual Funds
41.84% Other Institutional Investors
24.05% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---